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viduals with and without a recorded comorbid diagnosis of malnutrition, dehydra-
tion, UTI and aspiration pneumonia were compared. As there was a significant
interaction between number of comorbidities and hospital charge in the UTI and
pneumonia sample, an analysis of covariance (ANCOVA) model was employed to
adjust the UTI and pneumonia analyses for this influence. The model was adjusted
for complication diagnosis as a factor and both 1) number of comorbidities, and 2)
complication diagnosis and number of comorbidities interaction as covariates.
RESULTS: The most common complications reported in patients with a recorded
diagnosis of dysphagia were UTI (27%, n3424), pneumonia (26%, n3348), dehy-
dration (12%, n1507), and malnutrition (8%, n1027). Dysphagia patients with
complications had significantly higher mean hospital charges than those without
the complications UTI ($35,358 vs. $30,373, p0.001), pneumonia ($33,085 vs.
$31,184, p0.001), dehydration ($28,093 vs. $20,850, p0.001), and malnutrition
($37,192 vs. $34,747, p0.001), and MS ($32,406 vs. $23,726, p0.001).
CONCLUSIONS: Our results demonstrate that having to treat the complications of
dysphagia adds significantly to the cost of hospital care. Proactive management of
patients with dysphagia may confer substantial savings to hospitals.
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OBJECTIVES: To investigate the cost and incidence of adverse gastrointestinal (GI)
events caused by bisphosphonate therapy in Taiwan. METHODS: We conducted a
retrospective cohort study based on the National Health Insurance Research data-
base in Taiwan from 2005 to 2009. The inclusion criteria for the study cases were
patients 1) who sought inpatient or outpatient care for gastrointestinal problems
with ICD9-CM codes of GI-related diagnosis within 4 months after the initiation of
filling bisphosphonate prescription (the index date) for bisphosphonate, and 2)
who have no prior history of GI treatment 90 days before the index date. The costs
and incidence associated with GI adverse events were assessed based upon sur-
vival analysis and generalized linear models. RESULTS: A total of 114,086 patients
were included in this study. The GI incidence rate was lower in the group treated
with risedronate (16%) than alendronate (25%). The average time of onset of GI
event was longer after taking risedronate (1.6 months) than taking alendronate (1
month). The average direct medical cost associated with a GI event was $3147(USD)
and $6235 (USD) in group treated with risedronate and alendronate, respectively.
The distribution of costs of GI events was physician consultation fees (35%), exam-
ination fee (10%), drug costs including proton pump inhibitors (22%), H2-blocker
(14%), cytoprotectants (7%) and other GI related costs (12%). CONCLUSIONS: Bis-
phosphonate treatment of osteoporosis may involve adverse GI events and their
associated medical costs should be taken into account when evaluate cost-effec-
tiveness of treatment for osteoporosis.
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OBJECTIVES: Dysphagia has been previously shown to increase hospital length of
stay (LOS) (Altman et al, 2010). The objective of this study was to quantify the
difference in hospital charges between patients identified with and without dys-
phagia among commonly associated neuromuscular, neurologic and cardiovascu-
lar diseases. METHODS: Using 2008 Health Care Utilization Project (HCUP) data,
individuals with a hospital discharge diagnosis of stroke, Alzheimer’s disease (AD),
ALS, dementia, heart failure (HF), multiple sclerosis, cerebral palsy, Huntington’s
disease, and Parkinson’s disease (PD) were identified using ICD-9 CM diagnosis
codes. Within each disease state, the mean (10% trimmed) hospital charges for
individuals with a recorded diagnosis of dysphagia (ICD-9: 438.82, 787.2-787.29)
were compared to those without dysphagia. An analysis of covariance (ANCOVA)
model was employed to account for potential impact of comorbidities on hospital
charges. The model was adjusted for dysphagia diagnosis as a factor and both 1)
number of comorbidities, and 2) dysphagia diagnosis and number of comorbidities
interaction as covariates. RESULTS: Dyphasgia was most commonly diagnosed in
patients with stroke (41.2%, n11,736), dementia (0.6%, n1,126), AD (0.4%, n489)
and HF (0.3%, n2,087). Cerebral palsy, PD, HD, and ALS were excluded from the
analysis due to small dysphagia sample (n10). Patients with dysphagia demon-
strated higher mean hospital charges compared with non-dysphagia patients for
stroke ($32,531 vs. $26,004, p0.001), dementia ($26,836 vs. $23,445, p0.001), AD
($25,431 vs. $22,915, p0.001), HF ($30,686 vs. $26,984, p0.001), and MS ($32,406 vs.
$23,726, p0.001) adjusted for number of comorbidities. The magnitude and direc-
tion of the association between dysphagia and hospital charges were consistent in
both the bivariate and multivariate analyses. CONCLUSIONS: Our results demon-
strate that patients with conditions that are complicated by dysphagia cost hospi-
tals significantly more than similar patients without dysphagia and management
of these patients can avert significant costs.
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OBJECTIVES: Generic prescribing is important in South Africa. Many medical aid
schemes will only reimburse the cost of the generic product, and a co-payment is
required if a patient wants to use the originator product. The primary aim of this
study was to investigate originator versus generic prescribing focussing on proton
pump inhibitors (PPIs). METHODS: Prescription data were obtained from a private
medical aid administrator in South Africa. The data covered 2010 and included
medication, procedures and devices (a total of 2126264 records). For the purpose of
this study, only PPI medicine items were extracted and analysed (MIMS category
12.4.4). Basic descriptive statistics were calculated. RESULTS: A total of 20537 PPIs
were prescribed (only 18.56% on the chronic option of the medical aid schemes).
Five different PPI active ingredients were prescribed to 7060 patients (50.88% fe-
male patients). Omeprazole was the most often prescribed PPI, accounting for half
of all PPI prescribing (50.78%), followed by esomeprazole (19.83%) and lansoprazole
(18.04%). Eight different trade names of omeprazole were prescribed (one generic
product accounted for 56.00% of all omeprazole prescriptions and 56.08% of the
cost of omeprazole prescriptions). The originator product only accounted for 1.75%
of omeprazole prescribing frequency and 3.07% of prescribing cost. Only one trade
name of esomeprazole was prescribed (no generic equivalents) and nine trade
names of lansoprazole (the originator accounted for 1.43% of prescribing frequency
and 2.51% of cost). On average, esomeprazole had the highest average cost of
R308.97, followed by rabeprazole (R236.58). Both these products do not have generic
equivalents on the South African market. CONCLUSIONS: Further studies that
include dosage forms and prescribed daily doses (PDDs) should be conducted
alongside cost analyses. A clear difference between the prescribing and cost of
originator versus generic prescribing was detected in this study.
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OBJECTIVES: To determine the cost range for different forms of antyhelicobacter
therapy (first and second line) of the working age patients with gastric and duode-
num ulcer in Ukraine. METHODS: Different variants of (triple and quadrotherapy)
of traditional schemes of antihelicobacter therapy, recommended by “Maastriht”
(2005) have been used in the research. When treatment course costs determination
for antihelicobacter therapy for one patient, the expenses only for drugs included
in the tested schemes have been taken. The prices for drugs have been taken from
the information system “Medicinal preparations”, Morion Company (August 2010).
The currency rate to dollar (USA) on August 31, 2010 was 7,89:1. Medicinal prepa-
rations with minimal and maximal costs for the disease treatment course have
been included for the costs range evaluation for the course of antihelicobacter
therapy of the first and second line for one patient. RESULTS: The costs range of
antihelicobacter therapy of the first and second line in Ukraine is rather large, $
5,71– $ 238,55 and $ 5,78 – $ 149,26, respectively. It is connected with big difference
between the cost of original and generic drugs, included into antihelicobacter ther-
apy scheme. CONCLUSIONS: The cost for antihelicobacter gastric ulcer and duo-
denal therapy course with the use of original and foreign generics can be rather
high in Ukraine. In connection with it, when drugs choosing it is reasonable to use
pharmacoeconomics research results, that will help to optimize the state, insuar-
ing componies and patients expenses for the disease treatment.
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OBJECTIVES: To compare health care costs between patients who switched from a
branded proton pump inhibitor (PPI) to a generic PPI and vice versa.METHODS:We
conducted a retrospective database analysis using commercial enrollees from a
large US health plan from February 2008 to March 2010. Continuously eligible adult
patients who had gastroesophageal reflux disease (GERD) or GERD-related condi-
tions, and evidence of PPI use during February 2009 to September 2009 were in-
cluded. The index PPI was defined as the first PPI prescribed during the identifica-
tion period. The two cohorts in this study included patients who switched from a
generic PPI to a branded index PPI versus patients who switched from a branded
index PPI to a generic index PPI. Risk adjustment was performed using propensity
score matching. We controlled for age, gender, region, GERD severity, plan, pre-
index Quan-Charlson comorbidity score (CCI), baseline daily average consumption
(DACON), and baseline costs and utilization.RESULTS:A total of 9881 patients from
each cohort were matched after propensity score matching. During the 6 months
after the switch, there were no statistically significant differences between the two
cohorts in terms of office visit costs, outpatient costs, emergency services costs,
inpatient costs, and other costs., However, patients who switched to a generic PPI
had lower pharmacy costs ($1919 vs. $2306, p0.001). CONCLUSIONS: Although
pharmacy costs are slightly lower for patients who switched from a branded to a
generic PPI, there were no significant differences in other health care costs such as
for office visits, emergency room services, and inpatient visits.
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OBJECTIVES: Constipation is considered an inconvenient problem, however data
on the real burden is lacking. The objective of the current analysis was to assess the
clinical and economic burden of chronic constipation in Belgium.METHODS: From
the IMS Hospital Disease Database (year 2007), which includes data on full hospi-
talizations and day clinic for 34.3% of Belgian hospital beds, stays of patients with
constipation were selected based on the ICD-9-CM code (564.0) with constipation as
a primary diagnosis. The database allows to estimate length of stay (LOS), in-
hospital mortality, performed interventions, ATC classified medication usage, and
cost of hospitalisation. Using the 34% coverage, a national projection was made for
the number of hospital stays and burden of disease. 2007 costs were extrapolated to
2010 using progression in costs from 2001 to 2007. ATC codes for osmotic/contact
laxatives, softeners, bulking agents, enemas and peripheral opioid receptor antag-
onists were used. Occurrence of relevant co-morbidities was analyzed using appli-
cable ICD-9-CM codes. RESULTS: There were 6338 hospital day clinic stays and full
hospitalizations (LOS 5.44 days). About 42% of the patients were admitted via the
ER. Most occurring co-morbidities were hemorrhoids (174), fecal impaction (74) and
intestinal obstruction (53). Mortality rate was 0.46% meaning 29 deaths in hospi-
talizations for constipation. Especially in hospitalized patients, usage of enemas
was pronounced (34.17%). Osmotically acting laxatives are the most used agents
(39.58%). The average costs per patient was €1883, consisting of medication costs,
procedural costs and stay costs of €112, €675 and €1097, respectively. Extrapolated
to Belgium the total hospitalization cost for constipation was approximately €11.9
million. Hospital stay is more frequent in the elderly particularly in elderly females.
CONCLUSIONS: Constipation is an underestimated disease condition reflected by
hospital related costs of about €11.9 million and approximately 29 death cases in
Belgium in 2007.
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OBJECTIVES: The aim of this study was to assess disease stage dependent resource
use and costs in chronic genotype 1 hepatitis C (CHC) patients in Belgium.
METHODS: The medical records of 157 CHC patients were reviewed to identify
medical costs over a follow up period of 3 years. Six disease stages were defined
based on histology/clinical data: mild disease (F0-F2), moderate disease (F3) or
compensated cirrhosis without varices (F4), compensated cirrhosis with varices
(F4), decompensated cirrhosis, hepatocellular carcinoma (HCC) and liver trans-
plantation (LT). Data collected were baseline demographic characteristics, HCV-
related data and detailed resource use (hospitalizations, day-clinic visits, surgery/
interventions, physician visits, diagnostic tests and drug use). Resource use items
were multiplied with unit costs (2010) to calculate costs. The public health care
payer’s (HCP) perspective was taken including the health insurance and patient
co-payment. RESULTS: Intravenous/intranasal drug use was reported in circa 20%
of patients, 63% had co-morbidities at study start. Nineteen patients (12%) died
during the study period, whereof 79% attributable to HCV. Average number of
hospitalizations during the study period ranged between 0.4 (mild disease) and 5.3
(HCC). Cost of care during the study period ranged from €18,993 for mild disease (in
81% due to HCV drug treatment) to €35,987 for patients with HCC (in 83% due to
hospitalization, 11% due to medication and in 6% due to ambulatory care) and
€65,120 for patients who underwent a liver transplant (79% hospitalization, 18%
medication, 3% ambulatory care). Cost of diagnosis of the disease stage ranged
between €790 (F3-F4 without varices) and €4142 (decompensated cirrhosis).
CONCLUSIONS: Antiviral treatment is the most important cost driver in mild &
moderate disease, but once complications of CHC occur, the associated costs far
exceed this cost of antiviral therapy.
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OBJECTIVES: Hepatitis C (HCV) is a disease which in the long run can lead to
cirrhosis and liver cancer, resulting in liver transplantation or death if not treated
properly. So far, there is a paucity of literature on health care costs and quality of
life (QoL) of HCV management. This study aims to illustrate the health care costs
and QoL associated with HCV in The Netherlands. METHODS: This study followed
a cross-sectional design for QoL and indirect costs, and a retrospective design for
direct costs (these were mapped retrospectively until 3 years ago or diagnosis of
HCV if earlier). Patients with HCV genotype 1 at Erasmus MC were invited to par-
ticipate between November 2010 and April 2011. Patients were asked to complete
the EQ-5D, Short form 36 (SF-36), Liver disease symptom index (LDSI) and Short
form health and labour questionnaire (SF-HLQ). Resource use data were collected
from the hospital information system. Utilities were determined using the UK tariff
for EQ-5D The Mann-Whitney U-test was used for comparisons between treated
and non-treated patients for the disease categories, mild and moderate disease and
cirrhosis. RESULTS: Thirty-seven patients had either completed or discontinued
treatment during the observation period, 10 had achieved sustained viral response
(SVR). Mean direct costs were higher for treated patients, during all 3 years of
observation; 3286 versus 5361, 1336 versus 9440, 2538 versus 10.507, (p0.01). Com-
pared to non-responders successfully treated patients had lower follow-up costs 1
year after treatment, 1172 versus 1426, and a higher mean utility, 0.84 versus 0.70,
neither result was statistically significant at p0.4 and p0.2. There were no sig-
nificant differences in indirect costs. CONCLUSIONS: This study provides basic
information about the costs and utility of hepatitis C treatment. Such information
is valuable when considering cost-effectiveness of new treatments for this disease.
PGI16
COMPARISON OF TREATMENT AND INDIRECT COSTS BETWEEN HEPATITIS,
CIRRHOSIS, LIVER TRANSPLANTATION AND HEPATIC CARCINOMA: RESULTS
OF THE COME STUDY
Fusco F
Charta Foundation, Milano, Italy
OBJECTIVES: As a result of successful treatments for chronic hepatic diseases
(CHDs), patients’ life expectancy, but also the diseases prevalence and costs are
increasing. However, societal costs for CHDs remain little known. We assessed
treatment and productivity costs of patients with CHDs in Italy. METHODS: a nat-
uralistic multicentre Cost-of-Illness study was conducted. Adult patients (age18
years) diagnosed with CHDs, consequently accessing at gastroenterology unit of 2
hospitals, were enrolled. Direct and indirect costs were assessed from the societal
perspective, reported as mean €/patient-month (treatment cost) and mean days/
patient-month of work/school/usual activities lost (productivity loss). The patients
were sub-grouped according to their main condition at the enrollment: hepatitis B,
hepatitis C, cirrhosis, liver transplantation, hepatic carcinoma. RESULTS: We en-
rolled 1,088 valid patients, 62.0% male (N675), aged 19-90 (median60) years:
31.5% (N342) has hepatitis C, 20.3% (N220) cirrhosis, 19.8% (N216) hepatitis B,
11.9% (N129) had liver transplantation, 7.5%(N82) hepatic carcinoma, 9.0%
(N99) had other hepatic diseases. Overall, their treatment cost was 278.26 €/pa-
tient-month: 96% for conventional drug treatment, 4% for unconventional treat-
ment (homeopathy, preparation of herbs, specific diet, multi-vitamin products).
Patients who received liver transplantation were the most expensive (1041.31€/
patient-month), followed by hepatitis B (249 €/month), hepatitis C (167 €/month).
Productivity loss corresponded to 4.9 days/patient-month, mainly by transplanted
patients (8.6 days/patient-month) and those with cirrhosis (8 days/patient-month).
CONCLUSIONS: CHDs sensitively contribute to the high cost and require appropri-
ate health technology valuations to guide stakeholders to find optimal diagnostic
and treatment strategies.
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OBJECTIVES: There is no published study about the direct costs linked to the pro-
cedure of the EC in Brazil. Our aim was to determine a base price of a single
procedure of EC. METHODS: Based on a micro cost approach, we first determined
the individual items that compose an EC procedure. Then we conducted a market
price search for each of them in order to compose the final total cost. For the
permanent equipment needed we considered an amortization time of 24 months
and a 1% monthly interest percent rate. RESULTS: An EC procedure requires an
initial investment in one computer and in one receiver, which is attached to the
patient to capture the capsule’s signal, known as “belt”. Included in the analysis
there are also the cost of the capsule per si, some medicines, the physician’s and
the room fee. The initial investment is US$19,411. Each capsule cost US$647 (single
use). A medical fee of US$380 was set, that include the administration of the cap-
sule, the supervision of the patient during the length of the procedure and the
interpretation of the exam. Considering a service that performs three exams a
month, a cost of US$1645 would be necessary to cover the expenses with material,
personnel (doctors included) and to pay the amortization costs, insurance and
interests for a 24 months period. CONCLUSIONS: In Brazil, the cost of EC procedure
may be set at US$1645 in order to cover the expenses of the services.
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OBJECTIVES: Estimate long-term cost-effectiveness of treatment with peginter-
feron (pegINF) alfa-2a (180 mcg/week) in combination with ribavirin (RBV) (800 –
1200 mcg/day) versus pegINF alfa-2b (1.5 mcg/kg/week) in combination with RBV
(800- 1400 mg/day), in patients with Chronic Hepatitis C (CHC), from the Portuguese
National Health System (NHS) perspective. METHODS: To project disease progres-
sion, a seven-health state Markov model was built based on clinical stages of CHC.
Efficacy data was obtained from a published meta-analysis of 8 head-to-head ran-
domized trials that showed higher sustained virological response (SVR) in patients
receiving pegIFN alfa-2a compared to pegIFN alfa-2b. Effectiveness was measured
in terms of quality-adjusted life years. Transition probabilities and health state
utilities were obtained from published literature. Treatment duration was consid-
ered to be 48 and 24 weeks for genotypes 1/4 and 2/3, respectively. A Delphi panel
with Portuguese experts was conducted to evaluate direct medical resources asso-
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